Want to see BBNX full AI Analyst Report?

Beta Bionics, Inc. (BBNX) Stock Forecast & Price Target

84 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBNX Analyst Ratings

Moderate Buy

10 Buy

4 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Beta

Bionics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBNX Stock 12 Month Forecast

Average Price Target

$24.57

▲(28.84% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Beta Bionics, Inc. in the last 3 months. The average price target is $24.57 with a high forecast of $30.40 and a low forecast of $16.00. The average price target represents a 28.84% change from the last price of $19.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","20":"$20","31":"$31","14.5":"$14.5","25.5":"$25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.569230769230767,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14.5,20,25.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.87,19.756923076923076,20.643846153846155,21.53076923076923,22.417692307692306,23.304615384615385,24.19153846153846,25.07846153846154,25.965384615384615,26.85230769230769,27.73923076923077,28.626153846153844,29.513076923076923,{"y":30.4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.87,19.308402366863906,19.74680473372781,20.185207100591718,20.623609467455623,21.062011834319527,21.500414201183432,21.938816568047336,22.37721893491124,22.815621301775145,23.25402366863905,23.692426035502958,24.130828402366863,{"y":24.569230769230767,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.87,18.64923076923077,18.42846153846154,18.20769230769231,17.986923076923077,17.76615384615385,17.545384615384616,17.324615384615385,17.103846153846153,16.883076923076924,16.662307692307692,16.44153846153846,16.220769230769232,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.52,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.01,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.83,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.07,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.87,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.40

Average Price Target$24.57

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Toomey

Jefferies

$30

Buy

57.32%

Upside

Initiated

10/12/26

Beta Bionics initiated with a Buy at JefferiesBeta Bionics initiated with a Buy at Jefferies

Christopher Pasquale

Barclays

$30

Buy

57.32%

Upside

Initiated

10/06/26

Beta Bionics initiated with an Overweight at BarclaysBeta Bionics initiated with an Overweight at Barclays

Richard Newitter

Truist Financial

$23→$28

Buy

46.83%

Upside

Assigned

09/24/26

Beta Bionics, Inc. (BBNX) Receives a Buy from Truist Financial

Larry Biegelsen

Wells Fargo

$28

Buy

46.83%

Upside

Initiated

09/23/26

Beta Bionics initiated with an Overweight at Wells FargoBeta Bionics initiated with an Overweight at Wells Fargo

Frank Takkinen

Lake Street

$25

Buy

31.10%

Upside

Reiterated

09/22/26

Wall Street Analysts Are Bullish on Top NA Picks

Mike Kratky

Leerink Partners

$27

Buy

41.58%

Upside

Reiterated

09/17/26

Beta Bionics price target raised to $27 from $24 at LeerinkBeta Bionics price target raised to $27 from $24 at Leerink

Jeff Johnson

Robert W. Baird

$14→$16

Hold

-16.10%

Downside

Reiterated

09/15/26

Beta Bionics price target raised to $16 from $14 at BairdBeta Bionics price target raised to $16 from $14 at Baird

Jonathan Block

Stifel Nicolaus

$20→$22

Buy

15.36%

Upside

Reiterated

09/15/26

Beta Bionics, Inc. (BBNX) Receives a Buy from Stifel Nicolaus

Patrick Wood

UBS

$22→$25

Buy

31.10%

Upside

Reiterated

09/15/26

Beta Bionics price target raised to $25 from $22 at UBSBeta Bionics price target raised to $25 from $22 at UBS

Steven Lichtman

William Blair

―

Hold

―

Reiterated

09/14/26

Analysts Offer Insights on NA Companies: General Dynamics (NYSE: GD), Alphabet Class A (NASDAQ: GOOGL) and Beta Bionics, Inc. (NASDAQ: BBNX)

Mathew Blackman

TD Cowen

$16→$18

Hold

-5.61%

Downside

Reiterated

09/14/26

Analysts Offer Insights on NA Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Meta Platforms (NASDAQ: META) and Turn Therapeutics Inc (NASDAQ: TTRX)

Travis Steed

Bank of America Securities

$18→$20

Hold

4.88%

Upside

Reiterated

09/14/26

Analysts' Opinions Are Mixed on These NA Stocks: Beta Bionics, Inc. (NASDAQ: BBNX) and Pelthos Therapeutics (NYSE MKT: PTHS)

Jeffrey Cohen

Ladenburg Thalmann & Co.

$30.4

Buy

59.41%

Upside

Reiterated

07/30/26

Analysts Offer Insights on NA Companies: Beta Bionics, Inc. (NASDAQ: BBNX) and Waystar Holding Corp. (NASDAQ: WAY)

Matthew O'Brien

Piper Sandler

$20

Buy

4.88%

Upside

Reiterated

07/30/26

Piper Sandler Reaffirms Their Buy Rating on Beta Bionics, Inc. (BBNX)

David Roman

Goldman Sachs

$17→$19

Buy

-0.37%

Downside

Assigned

07/15/26

Beta Bionics price target raised to $19 from $17 at Goldman SachsBeta Bionics price target raised to $19 from $17 at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Toomey

Jefferies

$30

Buy

57.32%

Upside

Initiated

10/12/26

Beta Bionics initiated with a Buy at JefferiesBeta Bionics initiated with a Buy at Jefferies

Christopher Pasquale

Barclays

$30

Buy

57.32%

Upside

Initiated

10/06/26

Beta Bionics initiated with an Overweight at BarclaysBeta Bionics initiated with an Overweight at Barclays

Richard Newitter

Truist Financial

$23→$28

Buy

46.83%

Upside

Assigned

09/24/26

Beta Bionics, Inc. (BBNX) Receives a Buy from Truist Financial

Larry Biegelsen

Wells Fargo

$28

Buy

46.83%

Upside

Initiated

09/23/26

Beta Bionics initiated with an Overweight at Wells FargoBeta Bionics initiated with an Overweight at Wells Fargo

Frank Takkinen

Lake Street

$25

Buy

31.10%

Upside

Reiterated

09/22/26

Wall Street Analysts Are Bullish on Top NA Picks

Mike Kratky

Leerink Partners

$27

Buy

41.58%

Upside

Reiterated

09/17/26

Beta Bionics price target raised to $27 from $24 at LeerinkBeta Bionics price target raised to $27 from $24 at Leerink

Jeff Johnson

Robert W. Baird

$14→$16

Hold

-16.10%

Downside

Reiterated

09/15/26

Beta Bionics price target raised to $16 from $14 at BairdBeta Bionics price target raised to $16 from $14 at Baird

Jonathan Block

Stifel Nicolaus

$20→$22

Buy

15.36%

Upside

Reiterated

09/15/26

Beta Bionics, Inc. (BBNX) Receives a Buy from Stifel Nicolaus

Patrick Wood

UBS

$22→$25

Buy

31.10%

Upside

Reiterated

09/15/26

Beta Bionics price target raised to $25 from $22 at UBSBeta Bionics price target raised to $25 from $22 at UBS

Steven Lichtman

William Blair

―

Hold

―

Reiterated

09/14/26

Analysts Offer Insights on NA Companies: General Dynamics (NYSE: GD), Alphabet Class A (NASDAQ: GOOGL) and Beta Bionics, Inc. (NASDAQ: BBNX)

Mathew Blackman

TD Cowen

$16→$18

Hold

-5.61%

Downside

Reiterated

09/14/26

Analysts Offer Insights on NA Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Meta Platforms (NASDAQ: META) and Turn Therapeutics Inc (NASDAQ: TTRX)

Travis Steed

Bank of America Securities

$18→$20

Hold

4.88%

Upside

Reiterated

09/14/26

Analysts' Opinions Are Mixed on These NA Stocks: Beta Bionics, Inc. (NASDAQ: BBNX) and Pelthos Therapeutics (NYSE MKT: PTHS)

Jeffrey Cohen

Ladenburg Thalmann & Co.

$30.4

Buy

59.41%

Upside

Reiterated

07/30/26

Analysts Offer Insights on NA Companies: Beta Bionics, Inc. (NASDAQ: BBNX) and Waystar Holding Corp. (NASDAQ: WAY)

Matthew O'Brien

Piper Sandler

$20

Buy

4.88%

Upside

Reiterated

07/30/26

Piper Sandler Reaffirms Their Buy Rating on Beta Bionics, Inc. (BBNX)

David Roman

Goldman Sachs

$17→$19

Buy

-0.37%

Downside

Assigned

07/15/26

Beta Bionics price target raised to $19 from $17 at Goldman SachsBeta Bionics price target raised to $19 from $17 at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beta Bionics, Inc.

3 Months

David RomanGoldman Sachs

Success Rate

4/5 ratings generated profit

Average Return

+33.02%

Copying David Roman's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +33.02% per trade.

1 Year

Frank TakkinenLake Street

Success Rate

7/12 ratings generated profit

Average Return

+4.24%

Copying Frank Takkinen's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +4.24% per trade.

2 Years

Matthew O'BrienPiper Sandler

Success Rate

6/10 ratings generated profit

Average Return

+5.93%

Copying Matthew O'Brien's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +5.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBNX Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBNX has received 10 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BBNX average Analyst price target in the past 3 months is 24.57.

Each month's total comprises the sum of three months' worth of ratings.

BBNX Financial Forecast

BBNX Earnings Forecast

Next quarter’s earnings estimate for BBNX is -$0.52 with a range of -$0.59 to -$0.42. The previous quarter’s EPS was -$0.53. BBNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year BBNX has Performed in-line its overall industry.

BBNX Sales Forecast

Next quarter’s sales forecast for BBNX is $34.72M with a range of $33.90M to $35.58M. The previous quarter’s sales results were $32.01M. BBNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year BBNX has Performed in-line its overall industry.

BBNX Stock Forecast FAQ

What is BBNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Beta Bionics, Inc.’s 12-month average price target is 24.57.

What is BBNX’s upside potential, based on the analysts’ average price target?

Beta Bionics, Inc. has 28.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBNX a Buy, Sell or Hold?

Beta Bionics, Inc. has a consensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.

What is Beta Bionics, Inc.’s price target?

The average price target for Beta Bionics, Inc. is 24.57. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.40 ,the lowest forecast is $16.00. The average price target represents 28.84% Increase from the current price of $19.07.

What do analysts say about Beta Bionics, Inc.?

Beta Bionics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of BBNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Beta Bionics, Inc. (BBNX) Stock Forecast & Price Target

BBNX Analyst Ratings

BBNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Beta Bionics, Inc.

BBNX Analyst Recommendation Trends

BBNX Financial Forecast

BBNX Earnings Forecast

BBNX Sales Forecast

BBNX Stock Forecast FAQ

Detailed List of Analyst Forecasts